Related Experiment Video
Updated: Sep 28, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Estrogen receptor-mediated actions of polyphenolic catechins in vivo and in vitro
M G Goodin1, K C Fertuck, T R Zacharewski
1Department of Pharmacology and Toxicology, University of Otago, 18 Frederick Street, Rm. 238 Adams Building, Dunedin, New Zealand.
Abstract:
Recent investigations have demonstrated that polyphenolic catechins inhibit breast cancer cell proliferation and tumor growth. However, the ER-mediated effects of the three predominant catechins (EGCG, ECG, and EGC) have not been extensively examined in vitro or in vivo. Therefore, EGCG, ECG, and EGC were examined for their ability to compete with [(3)H]-17beta-estradiol ([(3)H]-E(2)) for binding to ERalpha and ERbeta and to elicit reporter gene activity in MCF-7 human breast cancer cells transiently transfected with either chimeric ERalpha or ERbeta. EGCG and ECG displaced [(3)H]-E(2) from GST-hERalphadef (D, E, and F domains of human ERalpha fused to GST) or from full-length human ERbeta. Additionally, only EGCG elicited Gal4-hERalphadef and Gal4-mERbetadef-mediated reporter gene expression (EC(50) values: 28 and 19 micro M, respectively) in MCF-7 cells cotransfected with a Gal4-regulated luciferase reporter gene. In cotreatment experiments, EGCG (1-50 micro M) and ECG (1 micro M) decreased E(2)-induced (1 nM) ERbeta-mediated gene expression 35-50%. In vivo, no catechin induced estrogenic responses (uterine weight or uterine peroxidase activity) in immature C57BL/6 mice. However, when mice were cotreated with E(2) (10 micro g/kg/day, 3 days) and either EGCG (30 and 50 mg/kg/day, 3 days) or ECG (50 mg/kg/day, 3 days), uterine peroxidase activity was increased 2.3-fold above that elicited by E(2) alone. In conclusion, EGCG and ECG bind to ERalpha and ERbeta, but only EGCG elicited ER-mediated gene expression in vitro. However, both of these compounds moderately increased E(2)-inducible responses in vivo.
Insights
Polyphenolic catechins like EGCG and ECG bind to estrogen receptors (ERalpha and ERbeta). While EGCG activates ER-mediated gene expression in vitro, both catechins enhance estrogen-induced responses in vivo.
Area of Science:
- Molecular Endocrinology
- Cancer Biology
- Pharmacology
Background:
- Polyphenolic catechins are known to inhibit breast cancer cell proliferation.
- The estrogen receptor (ER)-mediated effects of key catechins (EGCG, ECG, EGC) require further investigation.
- Understanding these mechanisms is crucial for developing novel breast cancer therapies.
Purpose of the Study:
- To investigate the in vitro and in vivo ER-mediated effects of EGCG, ECG, and EGC.
- To determine the binding affinity of these catechins to ERalpha and ERbeta.
- To assess their ability to modulate ER-mediated gene expression and estrogenic responses.
Main Methods:
- In vitro assays: Competition binding assays with [(3)H]-17beta-estradiol ([(3)H]-E(2)) and ERalpha/ERbeta.
- Reporter gene assays in MCF-7 cells to measure ERalpha/ERbeta-mediated gene activity.
- In vivo studies in mice to evaluate estrogenic responses (uterine weight, uterine peroxidase activity) with catechin cotreatment.
Main Results:
- EGCG and ECG demonstrated binding to both ERalpha and ERbeta.
- Only EGCG induced ER-mediated reporter gene expression in vitro.
- Both EGCG and ECG enhanced E(2)-induced uterine peroxidase activity in vivo, suggesting a moderate increase in estrogenic response.
Conclusions:
- EGCG and ECG interact with ERalpha and ERbeta, with EGCG showing direct gene activation in vitro.
- Both catechins can modulate estrogenic pathways in vivo, potentially influencing estrogen-dependent processes.
- These findings highlight the complex role of catechins in ER signaling and breast cancer.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Cancer Prevention
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

